Cellectis SA (CLLS) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Cellectis SA is set to present groundbreaking data on their gene-editing technologies at the ESGCT Annual Congress, showcasing advancements in TALE base editors and non-viral gene insertion methods. These developments could significantly enhance therapeutic applications, offering promising new avenues for gene therapy in hematopoietic stem and progenitor cells. Investors may find these innovations indicative of Cellectis’ potential for influencing future gene therapy markets.
For further insights into CLLS stock, check out TipRanks’ Stock Analysis page.